Dr. Suzanne Denise Debrosse, MD

Dr. Debrosse practices at University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System.

Dr. Debrosse's NPI, 1720293160, was assigned on May 11, 2007. Dr. Debrosse graduated from Cleveland Medical College, Homeopathic in 2004. Dr. Debrosse holds Ohio license 35.094127.

Dr. Debrosse's primary practice is University Hospitals Cleveland Medical Center, at 11100 Euclid Avenue, Cleveland, OH 44106 in Cuyahoga County. The practice phone is (216) 844-1000.

Dr. Debrosse's primary practice is University Hospitals Cleveland Medical Center in Cleveland, Ohio, part of University Hospitals Health System. Dr. Debrosse is also affiliated with University Hospitals Rainbow Babies & Children's Hospital. The medical group on file is University Hospitals Medical Practices.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Debrosse practices, 2 sites in all. Vendor and product names are available with a free account.

Clinical genetics (m.d.) is Dr. Debrosse's primary specialty in the NPI Registry, under taxonomy code 207SG0201X. Dr. Debrosse is board certified in clinical genetics and genomics by the American Board of Medical Genetics and Genomics. Dr. Debrosse is licensed in Ohio.

Dmand AI lists obesity among the conditions Dr. Debrosse treats.

CMS data shows 18 Medicare services from Dr. Debrosse across 1 procedure code in 2024, all of them office visits, for 33 Medicare patients. Medicare paid $1,726 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 33 Medicare patients who saw Dr. Debrosse in 2024. The largest group is under 65, with 13 patients. 64% of them have high cholesterol, and 61% have high blood pressure. 36% are also on Medicaid. Their average risk score is 1.29, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Debrosse's median patient age at 16, with 53% women.

In 2017, Dr. Debrosse wrote 11 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $574 in total drug cost. In 2016, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Debrosse for performance year 2024, reported as part of a group. Dr. Debrosse accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Debrosse as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 33 papers to Dr. Debrosse, published from 2012 to 2023. 2017 was the busiest year, with 7. The most frequent topics are Phenotype, Intellectual Disability and Mitochondrial Diseases. Dr. Debrosse has published most often in Mol Genet Metab. Dr. Debrosse's most frequent co-authors are Jirair Krikor Bedoyan, MD, PhD, Aga Julia Lewelt, MD and Matthew Thomas Sweney, MD.

Dmand AI links Dr. Debrosse to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Pyruvate Dehydrogenase Complex Deficiency Disease and Pyruvate Metabolism, Inborn Errors.

CMS Open Payments shows 1 general payment to Dr. Debrosse from 1 drug or device company in 2018. Food and beverage make up the largest share, 100% of the total. Biogen, Inc. paid the most, $104.

Dr. Debrosse graduated from Cleveland Medical College, Homeopathic in 2004. Dr. Debrosse is a member of AAN, American College of Medical Genetics and Genomics and AMA.

Dr. Debrosse is in network with 14 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Elevance. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.